Developer docs
API playgroundTry for free, no card

Search company profiles

Juniper Biologics

Full company profile

uuid000a2ry

Namestring
Juniper Biologics
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Juniper Biologics is a Singapore-based, privately held biopharmaceutical company focused on developing and commercializing novel therapies across oncology, rare/orphan diseases, and osteoarthritis. The company's stated therapeutic focus spans three distinct verticals, though its current operational footprint centers on a single asset: a gene therapy for knee osteoarthritis in-licensed from Kolon Life Science in April 2022 via a $600 million transaction. This acquisition represents the company's primary product offering and its entry into gene therapy for degenerative musculoskeletal conditions.

The company operates with a small team of 11-50 employees and is led by CEO Raman Singh. Its core technology is gene therapy, specifically applied to musculoskeletal indications through the acquired Kolon Life Science asset. There is no evidence in the source data of proprietary AI/ML capabilities, in-house research platforms, or broader pipeline assets beyond the single acquired therapy. Operating geographies, distribution channels, pricing models, and customer details are not disclosed in the available information.

The business model and revenue mechanics are not evidenced in the source material — no pricing details, distribution arrangements, or revenue figures are disclosed. The company's stated customer segment is healthcare providers and patients suffering from knee osteoarthritis, with the therapy positioned as an innovative biologic treatment for a degenerative joint condition. Given the very thin commercial disclosure, the company's monetization pathway appears to be in early or pre-commercial stages, with the $600 million asset acquisition suggesting either a licensing/royalty-based approach or future direct commercialization following regulatory approval.

Short descriptiontext

Juniper Biologics is a Singapore-based biopharmaceutical company developing novel therapies in oncology, rare diseases, and osteoarthritis, with its current core asset being a gene therapy for knee osteoarthritis acquired from Kolon Life Science.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
gene therapy, biopharmaceutical products, osteoarthritis treatment, oncology therapeutics, rare disease therapies
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Specialty Biopharmaceuticals
Social media profiles1 record
Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Juniper Biologics is a biopharmaceutical company developing novel therapies in oncology, rare/orphan diseases, and osteoarthritis. Its lead asset is a gene therapy for knee osteoarthritis, acquired from Kolon Life Science in April 2022 in a $600 million transaction. The company operates as a specialty biopharmaceutical entity focused on biologic therapeutics for degenerative joint conditions and high-need disease areas.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Juniper Biologics is a biopharmaceutical company operating as a single-product entity focused on gene therapy. The company's primary offering is a gene therapy treatment for knee osteoarthritis, acquired from Kolon Life Science in a $600 million deal. As a newer entrant in the biotech space, the company portfolio currently centers on this single acquired therapeutic product.

Product and service1 record
1Gene Therapy for Knee Osteoarthritis
CategoryBiologic Therapeutics / Gene Therapy
Description

A biologic gene therapy treatment for knee osteoarthritis, acquired from Kolon Life Science. Targeted at healthcare providers and patients with degenerative joint conditions who require disease-modifying biologic therapy. The therapy represents Juniper Biologics' lead commercial asset and primary pipeline focus.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Kolon Life Science
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-04-19
Description

Juniper Biologics acquired a gene therapy for knee osteoarthritis from Kolon Life Science. The deal was valued at $600 million, representing a significant strategic acquisition of biologic therapeutics technology for treating osteoarthritis.

bioworld.com
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global pharmaceutical incumbent with an established gene therapy portfolio (acquired through Beam Bio and Global Blood). Comparable as a major biopharma player with overlapping modality focus and significant osteoarthritis / musculoskeletal commercial footprint.

TypeBroad incumbent
Description

Major biopharmaceutical company that has aggressively expanded into gene and cell therapy (e.g., Casgevy approval). Comparable as an established biopharma with significant gene therapy investment and rare disease focus.

TypeRegional player
Description

Korean-based biologics contract development and manufacturing organization. Comparable as a regional (APAC) biologics player serving the broader biopharmaceutical ecosystem, including potential manufacturing partner dynamics for Juniper's gene therapy.

TypeDirect peer
Description

Established biopharmaceutical company with a marketed gene therapy (Roctavian) and pipeline across rare diseases. Comparable as a gene therapy company targeting rare/orphan indications with similar regulatory and commercialization challenges.

TypeDirect peer
Description

Gene therapy platform company developing AAV-based treatments across multiple therapeutic areas including rare diseases. Comparable as a gene therapy technology platform pursuing multiple indications, similar in modality focus to Juniper.

TypeBroad incumbent
Description

Global pharmaceutical leader with approved gene therapies (Kymriah, Zolgensma). Comparable as a large incumbent operating broadly in gene therapy and adjacent biologic modalities.

TypeDirect peer
Description

U.S.-based commercial-stage gene therapy company focused on rare diseases, with multiple approved and clinical-stage gene therapies. Highly comparable as a focused gene therapy company pursuing high-need indications with similar regulatory and commercial dynamics.

TypeDirect peer
Description

Clinical-stage gene therapy company developing treatments for rare and serious diseases. Comparable as a focused gene therapy developer with similar development-stage profile and reliance on platform technology.

9Bluebird Bio
TypeDirect peer
Description

Gene therapy company developing treatments for severe genetic diseases and cancer. Comparable as a single-modality gene therapy developer facing similar clinical, manufacturing, and commercialization risks.

10Kolon Life Science
TypeDirect peer
Description

Korean biopharmaceutical company that developed and transferred the gene therapy for knee osteoarthritis to Juniper Biologics. Closely comparable as the originator of Juniper's core asset and a gene therapy developer with overlapping therapeutic focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Juniper Biologics

Specialty Biopharmaceuticalsjuniperbiologics.com

Juniper Biologics is a Singapore-based biopharmaceutical company developing novel therapies in oncology, rare diseases, and osteoarthritis, with its current core asset being a gene therapy for knee osteoarthritis acquired from Kolon Life Science.

What Juniper Biologics does

Juniper Biologics is a Singapore-based, privately held biopharmaceutical company focused on developing and commercializing novel therapies across oncology, rare/orphan diseases, and osteoarthritis. The company's stated therapeutic focus spans three distinct verticals, though its current operational footprint centers on a single asset: a gene therapy for knee osteoarthritis in-licensed from Kolon Life Science in April 2022 via a $600 million transaction. This acquisition represents the company's primary product offering and its entry into gene therapy for degenerative musculoskeletal conditions.

The company operates with a small team of 11-50 employees and is led by CEO Raman Singh. Its core technology is gene therapy, specifically applied to musculoskeletal indications through the acquired Kolon Life Science asset. There is no evidence in the source data of proprietary AI/ML capabilities, in-house research platforms, or broader pipeline assets beyond the single acquired therapy. Operating geographies, distribution channels, pricing models, and customer details are not disclosed in the available information.

The business model and revenue mechanics are not evidenced in the source material — no pricing details, distribution arrangements, or revenue figures are disclosed. The company's stated customer segment is healthcare providers and patients suffering from knee osteoarthritis, with the therapy positioned as an innovative biologic treatment for a degenerative joint condition. Given the very thin commercial disclosure, the company's monetization pathway appears to be in early or pre-commercial stages, with the $600 million asset acquisition suggesting either a licensing/royalty-based approach or future direct commercialization following regulatory approval.

Juniper Biologics firmographics

Firmographics
Name
Juniper Biologics
Website
https://juniperbiologics.com
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
Juniper Biologics is a Singapore-based biopharmaceutical company developing novel therapies in oncology, rare diseases, and osteoarthritis, with its current core asset being a gene therapy for knee osteoarthritis acquired from Kolon Life Science.
Ownership category
akta.pro rank

Where Juniper Biologics is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Markets served

Juniper Biologics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Juniper Biologics product offering

Product offering

Core offering

Juniper Biologics is a biopharmaceutical company developing novel therapies in oncology, rare/orphan diseases, and osteoarthritis. Its lead asset is a gene therapy for knee osteoarthritis, acquired from Kolon Life Science in April 2022 in a $600 million transaction. The company operates as a specialty biopharmaceutical entity focused on biologic therapeutics for degenerative joint conditions and high-need disease areas.

Product overview

Juniper Biologics is a biopharmaceutical company operating as a single-product entity focused on gene therapy. The company's primary offering is a gene therapy treatment for knee osteoarthritis, acquired from Kolon Life Science in a $600 million deal. As a newer entrant in the biotech space, the company portfolio currently centers on this single acquired therapeutic product.

Differentiator

Problem solved

Functional benefit

Products and services

  • Gene Therapy for Knee Osteoarthritis A biologic gene therapy treatment for knee osteoarthritis, acquired from Kolon Life Science. Targeted at healthcare providers and patients with degenerative joint conditions who require disease-modifying biologic therapy. The therapy represents Juniper Biologics' lead commercial asset and primary pipeline focus.

Companies that use Juniper Biologics

Customer profile

Segments1 record

Ideal customer profiles1 record

Juniper Biologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Juniper Biologics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Kolon Life SciencecoreStrategic or Co-development Partner · 19 April 2022Juniper Biologics acquired a gene therapy for knee osteoarthritis from Kolon Life Science. The deal was valued at $600 million, representing a significant strategic acquisition of biologic therapeutics technology for treating osteoarthritis.

Scale indicators1 record

Recent moves3 records

Expansion highlights3 records

Juniper Biologics competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Global pharmaceutical incumbent with an established gene therapy portfolio (acquired through Beam Bio and Global Blood). Comparable as a major biopharma player with overlapping modality focus and significant osteoarthritis / musculoskeletal commercial footprint.
  • Vertex Pharmaceuticals: Major biopharmaceutical company that has aggressively expanded into gene and cell therapy (e.g., Casgevy approval). Comparable as an established biopharma with significant gene therapy investment and rare disease focus.
  • Novartis: Global pharmaceutical leader with approved gene therapies (Kymriah, Zolgensma). Comparable as a large incumbent operating broadly in gene therapy and adjacent biologic modalities.

Regional players

  • Samsung Biologics: Korean-based biologics contract development and manufacturing organization. Comparable as a regional (APAC) biologics player serving the broader biopharmaceutical ecosystem, including potential manufacturing partner dynamics for Juniper's gene therapy.

Direct peers

  • BioMarin Pharmaceutical: Established biopharmaceutical company with a marketed gene therapy (Roctavian) and pipeline across rare diseases. Comparable as a gene therapy company targeting rare/orphan indications with similar regulatory and commercialization challenges.
  • REGENXBIO: Gene therapy platform company developing AAV-based treatments across multiple therapeutic areas including rare diseases. Comparable as a gene therapy technology platform pursuing multiple indications, similar in modality focus to Juniper.
  • Sarepta Therapeutics: U.S.-based commercial-stage gene therapy company focused on rare diseases, with multiple approved and clinical-stage gene therapies. Highly comparable as a focused gene therapy company pursuing high-need indications with similar regulatory and commercial dynamics.
  • uniQure: Clinical-stage gene therapy company developing treatments for rare and serious diseases. Comparable as a focused gene therapy developer with similar development-stage profile and reliance on platform technology.
  • Bluebird Bio: Gene therapy company developing treatments for severe genetic diseases and cancer. Comparable as a single-modality gene therapy developer facing similar clinical, manufacturing, and commercialization risks.
  • Kolon Life Science: Korean biopharmaceutical company that developed and transferred the gene therapy for knee osteoarthritis to Juniper Biologics. Closely comparable as the originator of Juniper's core asset and a gene therapy developer with overlapping therapeutic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Juniper Biologics social profiles

Digital presence

Juniper Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Juniper Biologics leadership team

Management profile

Number of profiles

Profiles1 record

Juniper Biologics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Juniper Biologics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Juniper Biologics

What does Juniper Biologics do?

Juniper Biologics is a biopharmaceutical company developing novel therapies in oncology, rare/orphan diseases, and osteoarthritis. Its lead asset is a gene therapy for knee osteoarthritis, acquired from Kolon Life Science in April 2022 in a $600 million transaction. The company operates as a specialty biopharmaceutical entity focused on biologic therapeutics for degenerative joint conditions and high-need disease areas.

Is Juniper Biologics a public or private company?

Juniper Biologics is a private company. It is classified as unknown and is currently operating.

When was Juniper Biologics founded?

Juniper Biologics was founded in -1. It employs 11 to 50 people.

Where is Juniper Biologics based?

Juniper Biologics is headquartered in Singapore, Singapore, in the Asia region.

Who are Juniper Biologics's main competitors?

Broad incumbents on record are Pfizer, Vertex Pharmaceuticals and Novartis. Samsung Biologics is listed as a regional player. Direct peers are BioMarin Pharmaceutical, REGENXBIO, Sarepta Therapeutics, uniQure, Bluebird Bio and Kolon Life Science.

Does Juniper Biologics have an API?

No public API is recorded for Juniper Biologics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireJuniper Biologics Named "Pharmaceutical Company of the Year" at Corporate LiveWire Global AwardsJuniper Biologics, a Singapore-based pharmaceutical company founded in 2020, has been named "Pharmaceutical Company of the Year" by the Corporate LiveWire Global Awards for 2023-2024. The company specializes in Oncology, Gene Therapy, and Rare/Orphan Diseases, and recently secured exclusive licensing rights for the antiviral drug Ensitrelvir in Singapore. The award recognizes Juniper's dedication to advancing medical science and transforming patient care across Asia, Australia, New Zealand, the Middle East, and Africa.PR NewswireAdvancing Healthcare Innovation: Juniper Biologics Recognized as the Best Novel Therapy R&D and Commercialization Company 2024 by APAC InsiderJuniper Biologics, a Singapore-based pharmaceutical company focused on novel therapy research and commercialization, received the Best Novel Therapy R&D and Commercialization Company award at the APAC Insider Singapore Business Awards 2024. Since its founding in 2020, the company has developed capabilities in Oncology, Gene Therapy, and Rare Diseases, and recently secured exclusive rights to license the antiviral drug Ensitrelvir in Singapore for COVID-19. The company operates across Asia, Australia, New Zealand, the Middle East, and Africa, backed by The Sylvan Group.PR NewswireSingapore-based Juniper Biologics Awarded the Most Innovative Oncology Pharmaceutical Company 2023 by GHP Healthcare and Pharmaceutical AwardsJuniper Biologics, a Singapore-based pharmaceutical company, has been awarded the "Most Innovative Oncology Pharmaceutical Company 2023" by Global Health & Pharma at the GHP Healthcare and Pharmaceutical Awards. The recognition highlights the company's work in oncology treatments, including its acquisition of WHO Essential Medicines List therapies, and its commercial expansion across Asia, Australia, New Zealand, the Middle East, and Africa. CEO Raman Singh credited the award to the team's dedication and reaffirmed the company's commitment to developing innovative cancer therapies for unmet medical needs.PR NewswireJUNIPER BIOLOGICS PARTNERS WITH CARIS LIFE SCIENCES® FOR MOLECULAR PROFILING DISTRIBUTION IN SOUTH EAST ASIAJuniper Biologics, a Singapore-headquartered healthcare company, has been granted exclusive distribution rights for Caris Life Sciences' molecular profiling services across South East Asia. The partnership will provide oncologists in the region with access to Caris's comprehensive tumor profiling technology, including Whole Exome and Whole Transcriptome Sequencing across 22,000+ genes, to guide personalized cancer treatment decisions. The collaboration aims to improve cancer care options for patients with rare or aggressive cancers by enabling precision medicine approaches.PR NewswireJUNIPER BIOLOGICS PARTNERS WITH CARIS LIFE SCIENCES® FOR MOLECULAR PROFILING DISTRIBUTION IN SOUTH EAST ASIAJuniper Biologics, a Singapore-headquartered healthcare company, has been granted exclusive distribution rights for Caris Life Sciences' molecular profiling services across South East Asia. The partnership enables oncologists in the region to access Caris's comprehensive tumor profiling technology, including Whole Exome and Whole Transcriptome Sequencing, to guide personalized cancer treatment decisions. Caris Life Sciences, headquartered in the U.S., views this collaboration as supporting its goal of expanding access to its diagnostic technologies globally.PR NewswireJUNIPER BIOLOGICS WINS M&A AWARD 2022 BY ACQUISITION INTERNATIONALJuniper Biologics, a Singapore-headquartered healthcare company, received Acquisition International's M&A Award 2022 for Best Cell & Gene Therapy Acquisition for completing an up to $600 million deal to license TG-C LD, the world's first cell-mediated gene therapy for knee osteoarthritis. The treatment targets an estimated 300 million patients across Asia Pacific, the Middle East, and Africa, addressing one of the leading causes of disability globally. The CEO indicated the award recognizes the company's commitment to providing innovative treatments for unmet medical needs, with plans to pursue further acquisitions in therapeutic areas of high patient impact.PR NewswireJUNIPER BIOLOGICS WINS M&A AWARD 2022 BY ACQUISITION INTERNATIONALJuniper Biologics, a Singapore-headquartered healthcare company, was awarded Acquisition International's M&A Award 2022 for Best Cell & Gene Therapy Acquisition for completing a licensing deal worth up to $600 million to develop and commercialize TG-C LD, the world's first cell-mediated gene therapy for knee osteoarthritis. The treatment targets an estimated 300 million patients across Asia Pacific, the Middle East, and Africa who suffer from the degenerative joint disease, offering a non-surgical single-injection alternative to surgery. CEO Raman Singh stated the award recognises their commitment to providing innovative treatments for unmet medical needs and supports their strategy to pursue further acquisitions with positive patient impact.GlobeNewswireHelsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East*Helsinn and Juniper Biologics signed an exclusive distribution license for LEDAGA (chlormethine gel) to treat mycosis fungoides-type cutaneous T-cell lymphoma in Australia, Asia, and the Middle East. The gel is approved in the EU and US, and the license covers 28 countries. The deal expands geographic access for patients with MF-CTCL.GlobeNewswireJuniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging marketsJuniper Biologics and Helsinn signed an exclusive license agreement to develop and commercialize infigratinib for cholangiocarcinoma in Australia, New Zealand, Southeast Asia, and certain Middle East and African markets. Infigratinib received accelerated FDA approval for this indication in 2021, with continued approval contingent on confirmatory trials.